Original language | English |
---|---|
Pages (from-to) | 101-102 |
Number of pages | 2 |
Journal | Blood Cells, Molecules, and Diseases |
Volume | 77 |
DOIs | |
State | Published - Jul 2019 |
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Blood Cells, Molecules, and Diseases, Vol. 77, 07.2019, p. 101-102.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Addendum to Letter to the Editor
T2 - Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
AU - Mistry, Pramod K.
AU - Balwani, Manisha
AU - Baris, Hagit N.
AU - Turkia, Hadhami Ben
AU - Burrow, T. Andrew
AU - Charrow, Joel
AU - Cox, Gerald F.
AU - Danda, Sumita
AU - Dragosky, Marta
AU - Drelichman, Guillermo
AU - El-Beshlawy, Amal
AU - Fraga, Cristina
AU - Freisens, Selena
AU - Gaemers, Sebastiaan
AU - Hadjiev, Evgueniy
AU - Kishnani, Priya S.
AU - Lukina, Elena
AU - Maison-Blanche, Pierre
AU - Martins, Ana Maria
AU - Pastores, Gregory
AU - Petakov, Milan
AU - Peterschmitt, M. Judith
AU - Rosenbaum, Hanna
AU - Rosenbloom, Barry
AU - Underhill, Lisa H.
AU - Cox, Timothy M.
N1 - Funding Information: Pramod Mistry: Lead principle investigator in the eliglustat ENGAGE trial and principal investigator in the eliglustat ENCORE trial. Member of the International Collaborative Gaucher Group (ICCG) Gaucher Registry North American Advisory Board. Receives research support from Sanofi Genzyme and honoraria and travel reimbursement from Sanofi Genzyme.Hagit N. Baris: Principal investigator in the eliglustat ENGAGE trial. Recipient of research grants from Pfizer, Sanofi Genzyme, Shire, of honoraria from Sanofi Genzyme and Shire, of travel grants from Genzyme, Shire, Protalix and Pfizer and advisory board member of Sanofi Genzyme and Shire.Amal El Beshlawy: Principal investigator in the eliglustat ENCORE trial. Has received a research grant from Sanofi Genzyme.Priya Kishnani: Principal investigator in the eliglustat ENCORE trial. Received research/grant support from Sanofi Genzyme, Shire Pharmaceuticals, and Pfizer; and has received consulting fees and honoraria from Sanofi Genzyme, Shire Pharmaceuticals. Member of the ICGG Gaucher Registry Advisory Board for Sanofi Genzyme; Scientific Advisory Board for Shire Pharmaceuticals.Gregory Pastores: Principal investigator in the eliglustat ENGAGE and ENCORE trials. Has received grant/research support from Actelion, Alexion, Amicus/GSK, BioMarin, Sanofi Genzyme, Protalix BioTherapeutics/Pfizer, and Shire.Hanna Rosenbaum: Principal investigator in the eliglustat Phase 2 trial. Has received honoraria and travel reimbursement from Sanofi Genzyme. Recipient of research grants from Pfizer and Sanofi Genzyme.Timothy M. Cox: Lead principal investigator in the eliglustat ENCORE trial. Has received Honoraria, travel reimbursement and grant/research support from Shire Pharmaceuticals and an honorarium from Amicus/GSK. Funding Information: Hanna Rosenbaum: Principal investigator in the eliglustat Phase 2 trial. Has received honoraria and travel reimbursement from Sanofi Genzyme. Recipient of research grants from Pfizer and Sanofi Genzyme .
PY - 2019/7
Y1 - 2019/7
UR - http://www.scopus.com/inward/record.url?scp=85064623158&partnerID=8YFLogxK
U2 - 10.1016/j.bcmd.2019.04.003
DO - 10.1016/j.bcmd.2019.04.003
M3 - Letter
C2 - 31029022
AN - SCOPUS:85064623158
SN - 1079-9796
VL - 77
SP - 101
EP - 102
JO - Blood Cells, Molecules, and Diseases
JF - Blood Cells, Molecules, and Diseases
ER -